Four-Pronged attack on tough stomach cancers
NCT ID NCT06109467
Summary
This study is testing a new combination of four drugs for people with advanced stomach or esophageal cancer that has a specific genetic feature called HER2. The goal is to see if adding the drug neratinib to standard chemotherapy and two other targeted drugs is safe and can better shrink tumors. The trial will enroll 36 participants who have not yet received treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.